Lung Cancer Clinical Trial

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Summary

The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy.

The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and Women ≥ 18 years of age
Diagnosed with stage IV Non-Small Cell Lung Cancer
Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options.

Exclusion Criteria:

Subjects with untreated CNS metastases are excluded.
Subjects with carcinomatous meningitis
Subjects with an active, known or suspected autoimmune disease.
Subjects with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment.
Women who are pregnant, plan to become pregnant, and/or breastfeed during the study.

Other protocol defined inclusion/exclusion criteria apply

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

324

Study ID:

NCT02659059

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 27 Locations for this study

See Locations Near You

Sharp Memorial Hospital
San Diego California, 92123, United States
Cancer Center Of Central Connecticut
Plainville Connecticut, 06062, United States
Cleveland Clinic Florida
Weston Florida, 33331, United States
Winship Cancer Institute.
Atlanta Georgia, 30322, United States
Summit Cancer Care
Savannah Georgia, 31405, United States
Cancer Center Of Kansas
Wichita Kansas, 67214, United States
University Of Louisville Medical Center, Inc., Dba
Louisville Kentucky, 40202, United States
Johns Hopkins Cancer Center
Baltimore Maryland, 21287, United States
Beth Israel Deaconess Medical Center.
Boston Massachusetts, 02114, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02114, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Henry Ford Health System
Detroit Michigan, 48202, United States
Nebraska Hematology Oncology Pc
Lincoln Nebraska, 68506, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
New Mexico Hematology Oncology Consultants
Albuquerque New Mexico, 87106, United States
Lovelace Cancer Care
Albuquerque New Mexico, 87131, United States
New Mexico Cancer Care Alliance
Albuquerque New Mexico, 87131, United States
New Mexico Cancer Care Center
Albuquerque New Mexico, 87131, United States
The Cancer Center at Presbyterian
Albuquerque New Mexico, 87131, United States
Winthrop University Hospital
Mineola New York, 11501, United States
Memorial Sloan Kettering Nassau
New York New York, 10065, United States
Duke University
Durham North Carolina, 27710, United States
Novant Health Oncology Specialists
Winston-Salem North Carolina, 27103, United States
The Ohio State University
Columbus Ohio, 43210, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
Allegheny Health Network
Pittsburgh Pennsylvania, 15212, United States
Charleston Hematology Oncology Associates, Pa
Charleston South Carolina, 29414, United States
Tennessee Oncology, PLLC - SCRI - PPDS
Nashville Tennessee, 37203, United States
Vanderbilt University Medical Center
Nashville Tennessee, 37232, United States
Kingston Regional Cancer Centre
Kingston Ontario, K7L 2, Canada
Sault Area Hospital
Sault Ste Marie Ontario, P6B 0, Canada
Csss De St-Jerome
St. Jerome Quebec, J7Z 5, Canada

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

324

Study ID:

NCT02659059

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider